Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-021: Pembrolizumab Combinations in NSCLC
NCT02039674Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2014
- Primary completion
- Nov 2016
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
A Phase 2 trial of pembrolizumab in non-small cell lung carcinoma (NSCLC), sponsored by Merck & Co.. Started Feb 2014; status: completed.
02
Drugs
03
Conditions
non-small cell lung carcinoma (NSCLC)
Beyond the preview
Go deeper on NCT02039674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02039674.